Resmed announces small, easy to use home sleep apnea test, nightowl™, now available across the us

San diego, april 03, 2025 (globe newswire) -- resmed (nyse: rmd, asx: rmd), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced its home sleep apnea test, nightowl™, is now available across the united states. nightowl is an fda-cleared home sleep apnea test (hsat) designed to offer healthcare providers a simplified, accurate, and efficient way to diagnose obstructive sleep apnea (osa) from the comfort of an individual's home.
RMD Ratings Summary
RMD Quant Ranking